Virtual screening based identification of novel small-molecule inhibitors targeted to the HIV-1 capsid.

The hydrophobic cavity of the C-terminal domain (CTD) of HIV-1 capsid has been recently validated as potential target for antiviral drugs by peptide-based inhibitors; however, there is no report yet of any small molecule compounds that target this hydrophobic cavity. In order to fill this gap and discover new classes of ant-HIV-1 inhibitors, we undertook a docking-based virtual screening and subsequent analog search, and medicinal chemistry approaches to identify small molecule inhibitors against this target. This article reports for the first time, to the best of our knowledge, identification of diverse classes of inhibitors that efficiently inhibited the formation of mature-like viral particles verified under electron microscope (EM) and showed potential as anti-HIV-1 agents in a viral infectivity assay against a wide range of laboratory-adapted as well as primary isolates in MT-2 cells and PBMC. In addition, the virions produced after the HIV-1 infected cells were treated with two of the most active compounds showed drastically reduced infectivity confirming the potential of these compounds as anti-HIV-1 agents. We have derived a comprehensive SAR from the antiviral data. The SAR analyses will be useful in further optimizing the leads to potential anti-HIV-1 agents.

[1]  K. Nagashima,et al.  Mutation of Dileucine-Like Motifs in the Human Immunodeficiency Virus Type 1 Capsid Disrupts Virus Assembly, Gag-Gag Interactions, Gag-Membrane Binding, and Virion Maturation , 2006, Journal of Virology.

[2]  C. K. Chu,et al.  Synthesis, biological evaluation and molecular modeling studies of N6-benzyladenosine analogues as potential anti-toxoplasma agents. , 2007, Biochemical pharmacology.

[3]  David E. Martin,et al.  The discovery of a class of novel HIV-1 maturation inhibitors and their potential in the therapy of HIV , 2005, Expert opinion on investigational drugs.

[4]  A. Debnath,et al.  Solution Structure of a Hydrocarbon Stapled Peptide Inhibitor in Complex with Monomeric C-terminal Domain of HIV-1 Capsid* , 2008, Journal of Biological Chemistry.

[5]  David E. Martin,et al.  Potent Activity of the HIV-1 Maturation Inhibitor Bevirimat in SCID-hu Thy/Liv Mice , 2007, PloS one.

[6]  C. Aiken,et al.  Small-Molecule Inhibition of Human Immunodeficiency Virus Type 1 Replication by Specific Targeting of the Final Step of Virion Maturation , 2004, Journal of Virology.

[7]  P. Shenkin,et al.  Novel inhibitors of dengue virus methyltransferase: discovery by in vitro-driven virtual screening on a desktop computer grid. , 2010, Journal of medicinal chemistry.

[8]  I. Hewlett,et al.  HIV-1 capsid protein and cyclophilin a as new targets for anti-AIDS therapeutic agents. , 2007, Infectious disorders drug targets.

[9]  Jason Lanman,et al.  Investigation of N-terminal domain charged residues on the assembly and stability of HIV-1 CA. , 2004, Biochemistry.

[10]  Wesley I. Sundquist,et al.  Formation of a Human Immunodeficiency Virus Type 1 Core of Optimal Stability Is Crucial for Viral Replication , 2002, Journal of Virology.

[11]  Eric Barklis,et al.  Antiviral inhibition of the HIV-1 capsid protein. , 2003, Journal of molecular biology.

[12]  Wesley I. Sundquist,et al.  Image reconstructions of helical assemblies of the HIV-1 CA protein , 2022 .

[13]  E. Barklis,et al.  Virus Particle Core Defects Caused by Mutations in the Human Immunodeficiency Virus Capsid N-Terminal Domain , 2005, Journal of Virology.

[14]  Kunio Nagashima,et al.  In Vitro Resistance to the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PA-457 (Bevirimat) , 2006, Journal of Virology.

[15]  W. Guida,et al.  Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity , 2007, Proceedings of the National Academy of Sciences.

[16]  Wesley I. Sundquist,et al.  Assembly Properties of the Human Immunodeficiency Virus Type 1 CA Protein , 2004, Journal of Virology.

[17]  David E. Martin,et al.  Safety and Pharmacokinetics of Bevirimat (PA-457), a Novel Inhibitor of Human Immunodeficiency Virus Maturation, in Healthy Volunteers , 2007, Antimicrobial Agents and Chemotherapy.

[18]  William L Jorgensen,et al.  Discovery of novel fibroblast growth factor receptor 1 kinase inhibitors by structure-based virtual screening. , 2010, Journal of medicinal chemistry.

[19]  M. Emerman,et al.  Capsid Is a Dominant Determinant of Retrovirus Infectivity in Nondividing Cells , 2004, Journal of Virology.

[20]  S. Höglund,et al.  Mutation in the loop C-terminal to the cyclophilin A binding site of HIV-1 capsid protein disrupts proper virus assembly and infectivity , 2007, Retrovirology.

[21]  Anchi Cheng,et al.  Structure of Full-Length HIV-1 CA: A Model for the Mature Capsid Lattice , 2007, Cell.

[22]  Wesley I. Sundquist,et al.  Functional Surfaces of the Human Immunodeficiency Virus Type 1 Capsid Protein , 2003, Journal of Virology.

[23]  G. Verdine,et al.  An All-Hydrocarbon Cross-Linking System for Enhancing the Helicity and Metabolic Stability of Peptides , 2000 .

[24]  Hans-Georg Kräusslich,et al.  The HIV-1 capsid protein C-terminal domain in complex with a virus assembly inhibitor , 2005, Nature Structural &Molecular Biology.

[25]  W. Liao,et al.  A domain directly C-terminal to the major homology region of human immunodeficiency type 1 capsid protein plays a crucial role in directing both virus assembly and incorporation of Gag-Pol. , 2006, Virology.

[26]  Yu-Fen Chang,et al.  Mutations in capsid major homology region affect assembly and membrane affinity of HIV-1 Gag. , 2007, Journal of molecular biology.

[27]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[28]  Paul D Lyne,et al.  Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. , 2006, Journal of medicinal chemistry.

[29]  C. Lipinski.  Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[30]  S. Höglund,et al.  Selected amino acid substitutions in the C-terminal region of human immunodeficiency virus type 1 capsid protein affect virus assembly and release. , 2004, The Journal of general virology.

[31]  A. Debnath,et al.  A cell-penetrating helical peptide as a potential HIV-1 inhibitor. , 2008, Journal of molecular biology.

[32]  Mauricio G Mateu,et al.  Electrostatic repulsion, compensatory mutations, and long-range non-additive effects at the dimerization interface of the HIV capsid protein. , 2005, Journal of molecular biology.

[33]  J. Briggs,et al.  Structural organization of authentic, mature HIV‐1 virions and cores , 2003, The EMBO journal.

[34]  G. Pauli,et al.  Inhibition of infectious human immunodeficiency virus type 1 particle formation by Gag protein-derived peptides. , 1994, The Journal of general virology.

[35]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[36]  C. Wild,et al.  HIV-1 assembly and budding as targets for drug discovery. , 2005, Current opinion in investigational drugs.

[37]  H. Kräusslich,et al.  In vitro assembly properties of purified bacterially expressed capsid proteins of human immunodeficiency virus. , 1997, European journal of biochemistry.

[38]  Chun Tang,et al.  Structure of the antiviral assembly inhibitor CAP-1 complex with the HIV-1 CA protein. , 2007, Journal of molecular biology.

[39]  V. Vogt.  Blocking HIV-1 virus assembly , 2005, Nature Structural &Molecular Biology.

[40]  Marc C. Johnson,et al.  The Retroviral Capsid Domain Dictates Virion Size, Morphology, and Coassembly of Gag into Virus-Like Particles , 2005, Journal of Virology.

[41]  M. G. Mateu,et al.  The dimerization domain of the HIV‐1 capsid protein binds a capsid protein‐derived peptide: A biophysical characterization , 2004, Protein science : a publication of the Protein Society.

[42]  C. Aiken,et al.  Human Immunodeficiency Virus Type 1 Resistance to the Small Molecule Maturation Inhibitor 3-O-(3′,3′-Dimethylsuccinyl)-Betulinic Acid Is Conferred by a Variety of Single Amino Acid Substitutions at the CA-SP1 Cleavage Site in Gag , 2006, Journal of Virology.

[43]  T. Lovenberg,et al.  Lead identification of acetylcholinesterase inhibitors-histamine H3 receptor antagonists from molecular modeling. , 2008, Bioorganic & medicinal chemistry.

[44]  S. Höglund,et al.  Characterization of the invariable residue 51 mutations of human immunodeficiency virus type 1 capsid protein on in vitro CA assembly and infectivity , 2007, Retrovirology.

[45]  Curtis McMurtrey,et al.  3-O-(3′,3′-Dimethysuccinyl) Betulinic Acid Inhibits Maturation of the Human Immunodeficiency Virus Type 1 Gag Precursor Assembled In Vitro , 2006, Journal of Virology.

[46]  F. Förster,et al.  The mechanism of HIV-1 core assembly: insights from three-dimensional reconstructions of authentic virions. , 2006, Structure.

[47]  Ida-Maria Sintorn,et al.  Tripeptide Interference with Human Immunodeficiency Virus Type 1 Morphogenesis , 2002, Antimicrobial Agents and Chemotherapy.

[48]  David E. Martin,et al.  Phase I and II Study of the Safety, Virologic Effect, and Pharmacokinetics/Pharmacodynamics of Single-Dose 3-O-(3′,3′-Dimethylsuccinyl)Betulinic Acid (Bevirimat) against Human Immunodeficiency Virus Infection , 2007, Antimicrobial Agents and Chemotherapy.

[49]  Barbara Müller,et al.  A peptide inhibitor of HIV-1 assembly in vitro , 2005, Nature Structural &Molecular Biology.

[50]  A. Ghose,et al.  1,2,3-Thiadiazole substituted pyrazolones as potent KDR/VEGFR-2 kinase inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[51]  David E. Martin,et al.  PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[52]  W. Sundquist,et al.  Assembly and analysis of conical models for the HIV-1 core. , 1999, Science.

[53]  Li Huang,et al.  Anti-AIDS agents 81. Design, synthesis, and structure-activity relationship study of betulinic acid and moronic acid derivatives as potent HIV maturation inhibitors. , 2010, Journal of medicinal chemistry.